Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

• Status: Terminated
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to show that PET-MR imaging can be used for obtaining a pharmacodynamic profile of drugs. By using the 5-HT1B receptor as target we also aim to find effect areas and sizes of the 5-HT1B receptor agonist sumatriptan.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gitte Moos Knudsen
• Treatments: Sumatriptan

Criteria

Inclusion Criteria:

• Healthy subjects

• Age 18-60

Exclusion Criteria:

• Primary psychiatric disease (DSM IV Axis I or WHO ICD-10 diagnostic classification).

• Present or former neurological diseases,

• Severe somatic disease

• Medication that can interfere with the test results.

• Doesn't speak Danish fluently or is severely, visually or hearing impaired.

• Information regarding former learning disabilities.

• Pregnancy at the time of the scanning

• Breast feeding

• MR-scanner incompatibility (metal in soft tissue)

• Alcohol or drug abuse

• Allergy to ingredients in used drugs

• Participation in experiments with radioactivity (>10 mSv) within the last year or considerable work-related exposure to radioactivity.